Research Finds Previous Use of Antidepressants May Reduce MDMA Effectiveness Against PTSD

April 26, 2021 13:35:30

A study conducted recently proposes that psychedelic-assisted therapy using MDMA to help treat PTSD is not as efficacious among individuals who have recently used psychiatric drugs commonly prescribed by doctors, known as selective serotonin re-uptake inhibitors. The research findings were reported in the “Psychopharmacology” journal.

Allison Feduccia, director of education platform Psychedelic Support and author of the study, explained that antidepressants, in particular SSRIs and MDMA, bound themselves to the same receptors in an individual’s brain. She noted that if an individual used selective serotonin reuptake inhibitors and MDMA concurrently, the effects of the psychedelic would be decreased.  Feduccia added that before the study, it had not been known whether the use of these antidepressants would influence how individuals would feel after they ingested MDMA.

She further explained that the research was crucial because MDMA, which is commonly referred to as ecstasy, could soon be approved as a post-traumatic stress disorder treatment, adding that most individuals living with this condition were usually given SSRIs to help them manage the condition. Feduccia also noted that the objective of the research was to learn whether the outcome of the treatment could be affected by other drugs, in order to provide each patient with the best chance of success with the therapy treatment.

For their research, the investigators examined data from clinical trials that had discovered evidence that MDMA-assisted therapy helped decreased symptom severity in PTSD. The researchers then compared data obtained from 34 participants who had not been ingesting SSRIs to 16 participants who had reduced their use of SSRIs before the trial.

Among those who had reduced their use of reuptake inhibitors, 25% did not meet the post-traumatic stress disorder diagnostic criteria for the disease after undergoing therapy sessions. On the other hand, nearly 64% of the individuals who weren’t ingesting SSRIs did not meet the PTSD diagnostic criteria after undergoing therapy.

Study findings show that some drugs could potentially impact the effects individuals felt when they ingested a psychedelic drug. Feduccia explained that while MDMA usually increased diastolic and systolic blood pressure, the expected blood pressure increases weren’t as high in the individuals who had stopped using their reuptake inhibitors.

She noted that this evidence suggests that the effects of the psychedelic substance weren’t as intense for those participants and claimed that the individuals may have also been experiencing symptoms that occurred because they stopped using their medication. Feduccia strongly advises against discontinuing the use of prescription medications without consulting a health-care provider first.

These findings will certainly add to what is already known about different psychedelics. Other teams, such as the scientific team at Cybin Inc. (NEO: CYBN) (OTCQB: CLXPF), will also keep adding their findings to the advancement of this industry.

NOTE TO INVESTORS: The latest news and updates relating to Cybin Inc. (NEO: CYBN) (OTCQB: CLXPF) are available in the company’s newsroom at

About PsychedelicNewsWire

PsychedelicNewsWire (PNW) is a specialized content distribution company that (1) aggregates and distributes news and information on the latest developments in all aspects and advances of psychedelics and their use, (2) creates PsychedelicNewsBreaks designed to quickly update investors on important industry news, (3) leverages a team of expert editors to enhance press releases for maximum impact, (4) assists companies with the management and optimization of social media across a range of platforms, and (5) delivers unparalleled corporate communication solutions. PNW stays abreast of the latest information and has established a reputation as the go to source for coverage of psychedelics, therapeutics and emerging market opportunities. Our team of seasoned journalists has a proven track record of helping both public and private companies gain traction with a wide audience of investors, consumers, media outlets and the general public by leveraging our expansive dissemination network of more than 5,000 key syndication outlets. PNW is committed to delivering improved visibility and brand recognition to companies operating in the emerging markets of psychedelics.

To receive instant SMS alerts, text “Groovy” to 21000 (U.S. Mobile Phones Only)

For more information please visit

Please see full terms of use and disclaimers on the PsychedelicNewsWire website applicable to all content provided by PNW, wherever published or re-published:

Do you have questions or are you interested in working with PNW? Ask our Editor

PsychedelicNewsWire (PNW)
San Francisco, California
415.949.5050 Office

PsychedelicNewsWire is part of the InvestorBrandNetwork.